Liposomal Mupirocin Formulation for Systemic Delivery

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Mupirocin, an antibiotic effective against gram-positive bacteria, is limited to topical application due to rapid degradation in the bloodstream and high binding to plasma proteins, necessitating a formulation for systemic delivery that maintains drug stability and controlled release.

Innovation Solution

Liposomal formulation of mupirocin with an intraliposomal compartment containing cyclodextrin and a pH-dependent ionizable anion, which stabilizes the drug and allows for slow release at the infection site, enhancing therapeutic efficacy and shelf-life stability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If mupirocin is administered systemically, then therapeutic effect can be achieved, but the drug rapidly degrades in the bloodstream

Engineering Contradiction:
Improvedrug stabilityVSAvoidcirculation time
Core Design Contradiction:
ReliabilityVSDuration of action of moving object

Solution Approach 1:

Mupirocin is nested within liposomes, which are spherical vesicles with an aqueous core surrounded by a phospholipid bilayer membrane. The drug is encapsulated in the intraliposomal compartment, protecting it from degradation in the bloodstream while enabling systemic delivery to infection sites

Inventive Principle:
Principle #7Nested doll (Nesting)

Solution Approach 2:

Cyclodextrin acts as an intermediary substance within the liposomal compartment that forms inclusion complexes with mupirocin. This intermediary interaction stabilizes the drug, prevents its degradation, and controls its release kinetics, thereby extending circulation time while maintaining therapeutic efficacy

Inventive Principle:
Principle #24Intermediary (Mediator)

2Quantity of substance

If high drug loading is achieved in liposomes, then therapeutic dose is provided, but drug release may be too rapid

Engineering Contradiction:
Improvedrug loading concentrationVSAvoiddrug release rate
Core Design Contradiction:
Quantity of substanceVSDuration of action of moving object

Solution Approach 1:

The patent utilizes pH-dependent ionizable anions that change their ionization state in response to pH variations. In the acidic intraliposomal environment, the anions remain protonated and do not interact strongly with mupirocin, allowing high drug loading. Upon liposome administration, as pH increases in the extracellular environment, the anions become deprotonated and interact with mupirocin to slow its release, thereby controlling the release rate while maintaining high loading concentrations

Inventive Principle:
Principle #35Parameter changes

3Manufacturing precision

If cyclodextrin is used to enhance drug solubility, then loading efficiency improves, but drug release stability may be compromised

Engineering Contradiction:
Improveloading efficiencyVSAvoidrelease stability
Core Design Contradiction:
Manufacturing precisionVSStability of the object's composition

Solution Approach 1:

The patent applies local quality by creating different chemical environments in different locations: the intraliposomal compartment contains cyclodextrin and pH-dependent ionizable anions that stabilize mupirocin and control its release, while the extraliposomal environment provides systemic circulation conditions. This spatial differentiation of properties allows both high loading efficiency and stable release characteristics to coexist

Inventive Principle:
Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The liposomal formulation achieves high drug loading, prolonged circulation time, slow drug release, and superior therapeutic efficacy, making it suitable for systemic clinical use while maintaining stability and effectiveness.

Implementation Method 1

the intraliposomal compartment encapsulating mupirocin, at least one cyclodextrin compound

Methodology Applied
Scientific EffectInclusion complex formation: Absorption (physical)

Implementation Method 2

remote loading of mupirocin into the intra-liposome aqueous phase of liposomes encapsulating at least one CD and a pH dependent ionizable anion

Methodology Applied
Scientific EffectpH gradient-driven transport: Diffusion

Implementation Method 3

allowing for slow release at the infection site

Methodology Applied
Scientific EffectDiffusion: Diffusion

Data Source

PatentEP3142642B1Liposomal mupirocin
Publication Date: 2018.08.29 YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD
  • EP3142642B1 patent drawingFigure 1~2
  • EP3142642B1 patent drawingFigure 3A~3B
  • EP3142642B1 patent drawingFigure 4~5

AI summary

The present disclosure provides liposomes encapsulating mupirocin, with particular benefit for systemic therapeutically effective delivery. Also provided herein are pharmaceutical compositions comprising the liposomes and methods of using them. The liposomes comprise a lipid membrane and an intraliposomal compartment, the intraliposomal compartment encapsulating mupirocin, at least one cyclodextrin compound and a pH dependent ionizable anion, e.g. acetate.